Zydus Lifesciences Launches AI Powered CGM Devices Diasens and GlucoLive to Strengthen Diabetes Monitoring in India
Zydus Expands Companion Diagnostics Portfolio with Smart Glucose Monitoring
Zydus Lifesciences has launched two artificial intelligence powered continuous glucose monitoring devices, Diasens and GlucoLive, expanding its companion diagnostics portfolio as the demand for advanced chronic disease management tools grows in India.The next generation devices are designed to help patients with diabetes, chronic kidney disease, and individuals undergoing post transplant care. They enable continuous tracking of blood glucose levels while allowing clinicians to remotely monitor patient data in real time.
Real Time Monitoring Without Manual Scanning
Unlike many existing continuous glucose monitoring systems in India that require manual scanning using near field communication, the new devices automatically transmit glucose readings to a patient’s smartphone every three minutes.This includes overnight monitoring, enabling uninterrupted tracking and helping detect abnormal glucose trends at an early stage.
The system is integrated with artificial intelligence driven analytics and a clinician monitoring dashboard through the GoodFlip application. The platform has been developed by healthcare technology company Digicare Health Solutions, which has partnered with Zydus for the rollout.
Integrated Digital Health Platform for Patients and Doctors
Through the GoodFlip platform, patients can access several digital health services within a single application. These include AI driven glucose trend analysis, personalized diet and exercise recommendations, doctor consultations, diagnostic laboratory bookings, and a consolidated medical records vault.According to the company, the artificial intelligence layer analyzes glucose patterns and flags potential hypoglycemic or hyperglycemic episodes. It also links glucose fluctuations with food intake or physical activity, helping clinicians make timely treatment adjustments.
Addressing India’s Growing Diabetes Burden
India currently has more than 101 million adults living with diabetes, while another 136 million people are in the pre diabetic stage, according to the ICMR INDIAB study published in The Lancet Diabetes and Endocrinology.Diabetes is also a major contributor to chronic kidney disease in the country. Around 25 percent to 40 percent of patients with chronic kidney disease have a history of diabetes.
Despite the high prevalence of the disease, glucose monitoring in India largely remains episodic. Many patients rely on finger prick tests or periodic HbA1c checks conducted every few months, which often leaves gaps in clinical insight.
Zydus Lifesciences said the new AI enabled continuous glucose monitoring system is designed to address this gap by enabling continuous data capture and creating a connected ecosystem that links patients, caregivers, and clinicians in real time.
Zydus Lifesciences Share Price
Following the announcement, shares of Zydus Lifesciences closed largely unchanged at ₹915.65 on the NSE, down 0.66 percent.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.